Comparative Analysis of the QbD Approach in the Pharmaceutical Industry

Introduction. In the development and introduction of medicines into production, the aim of pharmaceutical manufacturers is to comply with the principle of «Quality-by-Design» (QbD). The International Council for Harmonisation (ICH) has created a number of GxP standards, which have become the regulatory framework for the development of documentation regulating the requirements for the development and production of drug products for countries focused on bringing their products to the world pharmaceutical market. The analysis of the system of regulation of pharmaceutical stages of development of new drugs in the territory of the Eurasian Economic Union was not considered, but for the formation of a systematic approach to the management of the process of pharmaceutical development it is necessary to describe them.

Aim. To analyze the possibility of applying the QbD principle to the process of drug development at domestic pharmaceutical enterprises.

Materials and methods. Content analysis of scientific publications, system and comparative analysis, sociological methods of research in the field of pharmaceutical development.

Results and discussions. Regulatory state requirements to the organization and conduct of drug development procedures are analyzed and described. A number of systemic and sectoral problems typical for domestic pharmaceutical manufacturers in the organization of the development and implementation of new drug products. It is established that one of the main problems for Russian enterprises was the organization of the process as a whole and its individual procedures. To solve the problem of organization of procedures for the development and implementation of new medicines, we formed a methodological support, developed on the basis of a systematic approach and international requirements from the quality system.

Conclusion. The main problem identified by the manufacturers is the lack of methodological support for the organization of the processes of pharmaceutical development and the introduction of new drugs in the part of research going to the stage of preclinical and clinical development. The decisions adopted by the Eurasian Economic Union do not affect such aspects of pharmaceutical development regulation as the organization of processes, their management and methodological support aimed at the implementation of the QbD principle. To solve this problem, we have developed guidelines for the implementation of the processes of pharmaceutical development and the introduction of new drug products, which allowed us to apply unified and formalized approaches to their organization. 

1. Ende D. J. Production of medicines. Chemical technology from R&D to production. – Saint Petersburg: Profession. 2015: 1280 (in Russ.).

2. Watson T. N. J., Nosal R., am Ende D., Bronk K., Mustakis J., O`Connor G., Santa Maria C. L. J. Pharmaceut. Innovation. 2007; 2(3-4): 71.

3. ICHQ8 Pharmaceuticaldevelopment. Avaliable at: http://www.ich.org.

4. ICHQ9 Risk Quality Management. Avaliable at: http://www.ich.org.

5. ICH Q10 Pharmaceutical Quality System. Avaliable at: http://www.ich.org.

6. ICH Q11 Development and manufacture of drug substances (chemical entities andbiotechnological/biological entities). Avaliable at: http://www.ich.org.

7. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human. Avaliable at: http://www.apteka.ua/article/296331.

8. Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Avaliable at: http://eurlex.europa.eu/homepage.html.

9. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. Avaliable at: http://eurlex.europa.eu/homepage.html

10. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Avaliable at: http://eur-lex.europa.eu/homepage.html.

11. Regulation (EC) No 726/2004 of the European Parliament and of the Council of31 March 2004 laying down Community procedures for the authorisationandsupervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Avaliable at: http://eur-lex.europa.eu/homepage.html (accessed 3.05.2018).

12. Commission Regulation (EC) No 540/95 of 10 March 1995 laying down thearrangements for reporting suspected unexpected adverse reactions which are notserious, whether arising in the Community or in a third country, to medicinalproducts for human or veterinary use authorized in accordance with the provisionsof Council Regulation (EEC) No 2309/93. Avaliable at: http://eur-lex.europa.eu/homepage.html.

13. Regulation (EC) No 596/2009of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Avaliable at: http://eurlex.europa.eu/homepage.html.

14. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (consolidated version: 26/01/2007). Avaliable at: http://eurlex.europa.eu/homepage.html.

15. Hilts P. J. Protecting America’s Health: The FDA, Business, and One Hundred years of Regulation and sources therein. 2003; 55: 46.

16. Veldanova M. From January 1 in the EAEU starts a single market of drugs. 2016. Avaliable at: www.gmpnews.ru/2016/01/eaes-sozdayotedinyj-rynok-obrashheni-ya-lekarstv-medizdelij-i-texniki.

17. Gavrilov D., Raschevsky E. Single market of medicines on the territory of the EAEU. 2016. Avaliable at: http://epam.ru/rus/legal-updates/view/edinyi-rynok-lekarstvennyh-sredstv-na-territorii-eaes.

18. Decision of the Council of the Eurasian economic Commission of November 3, 2016, No. 78 «Оn the rules of registration and examination of medicines for medical use». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_pravila-registraciilekarstvennih-sredstv.pdf.

19. Decision No. 77 of the Council of the Eurasian economic Commission of 3 November 2016 «Оn approval of the rules of good manufacturing practice of the Eurasian economic Union». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_pravila-GMP.pdf.

20. Decision of the Council of the Eurasian economic Commission dated November 3, 2016, No. 79 «Rules of good clinical practice of the Eurasian economic Union». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_GCP.pdf.

21. Decision of the Council of the Eurasian economic Commission dated November 3, 2016, No. 85 «Rules for bioequivalence studies of medicines within the Eurasian economic Union». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_issledovanijabioekvivalentnosti.pdf.

22. Decision of the Council of the Eurasian economic Commission of November 3, 2016, No. 89 «Rules for research of biological medicines of the Eurasian economic Union». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_issledovaniya-biologicheskihLS.pdf.

23. Decision No. 80 of the Council of the Eurasian economic Commission dated November 3, 2016 «Rules of good distribution practice within the Eurasian economic Union». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_GDP.pdf.

24. Decision of the Council of the Eurasian economic Commission of November 3, 2016, No. 81 «Rules of good laboratory practice of the Eurasian economic Union in the field of circulation of medicines». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_GLP.pdf.

25. Decision of the Council of the Eurasian economic Commission dated November 3, 2016, No. 87 «Rules of good practice of pharmacovigilance of the Eurasian economic Union». Avaliable at: http://www.fptl.ru/biblioteka/eaeunion_lekarstva/EAEU_farmakonadzor.pdf.

26. Bykovsky S. N., Vasilenko I. A., Demina N. B. Pharmaceutical development: concept and practical recommendations. Scientific and practical guide for the pharmaceutical industry. – M.: Publishing house Pero. 2015: 472 (in Russ.).

27. Demina N. B. Pharmaceutical development: review of equipment for laboratory development and development of experimental batches of solid dosage forms. Drug development & registration. 2016; 1(14): 38–46 (in Russ.).

28. Lin A. A., Sokolov B. I., Slepnev D. M. Pharmaceutical market: production of medicines in Russia. Problems of the modern economy. 2013; 1(45) : 191–195 (in Russ.).

29. Narkevich I. A., Trofimova E. O., Delvig-Kamenskaya T. Yu. The Problem of personnel training for the Russian pharmaceutical industry and ways to overcome it. Innovations. 2013; 7(177): 3–8 (in Russ.).

30. Narkevich I. A., Lin A. A., Denisova E. V. Investments in research and development in the global pharmaceutical market. Pharmacy. 2017; 66(3): 3–7. 2017; 66(3): 3–7 (in Russ.).

31. Potapchik E. G., Popovich L. D. Analysis of the world experience in the selection of projects implemented through public-private partnerships in the health sector. Health. 2015; 8: 66–75 (in Russ.).

32. Pyatigorskaya N. V., Beregovykh V. V., meshkovsky A. P., Pyatigorsky A. M., Bykov A.V. Оrganization of production and quality control of medicines. – M.: Publishinghouse RAMS. 2013: 648 (in Russ.).

33. Rozhnova S. A., Tsypkina A. V. The Analysis of methods used in the development of pharmaceutical substances. Scientific and practical journal pharmacy, special issue: «Collection of the conference» Young pharmacy-the potential of the future». 2018: 159–161 (in Russ.).

34. Rozhnova S. A., Tsypkina A. V. The Analysis of the system of organization of pharmaceutical development of medicines. Drug development & registration. 2017; 3(20): 170–178 (in Russ.).

35. Rozhnova S. A., Tsypkina A. V. Use of IDEF0 standard in preparation for pharmaceutical development. Drug development & registration. 2017; 4(21): 270–276 (in Russ.).

36. Rozhnova S. A., Tsypkina A. V. Use of the IDEF0 standard at the planning stage of pharmaceutical development. Collection of materials of the all-Russian scientific and practical conference with international participation. – Orekhovo-Zuyevo: Editorial and publishing Department of GSTU. 2017; 3(20): 216–220 (in Russ.).

37. Methodology of functional modeling RD IDEF0. Standards publishing House. 2000: 75.

38. Federal law No. 61-FZ of 24.03.2010 «On circulation of medicines». Avaliable at: http://www.consultant.ru/document/cons_doc_LAW_99350/

39. Order of the Ministry of industry and trade of Russia of 14.06.2013 No. 916 (ed. of 18.12.2015) «On approval of the Rules of good manufacturing practice». Avaliable at: http://www.vgnki.ru/assets/files/normativy/916.pdf.